Insider · CIK 0001864112

Kathiresan Sekar

Reports to the SEC for 3 companies · BOSTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0001864112

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-09-22	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+18K sh	—	—	18,000
2025-07-25	Verve Therapeutics, Inc.U Disposition from Tender	Director, Chief Executive Officer	UDisposition from Tender	−348K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.U Disposition from Tender	Director, Chief Executive Officer	UDisposition from Tender	−111K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.U Disposition from Tender	Director, Chief Executive Officer	UDisposition from Tender	−241K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−488K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−150K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−120K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−99K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−139K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−167K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−500K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−75.1K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−432K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, Chief Executive Officer	DDisposition to Issuer	−526K sh	—	—	0
2025-06-06	RLAYRelay Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+137K sh	—	—	136,681
2025-04-02	Verve Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−9,822 sh	$4.15	−$40.8K	346,686
2025-04-01	Verve Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+33K sh	—	—	356,508
2025-04-01	Verve Therapeutics, Inc.Restricted Stock UnitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−33K sh	—	—	99,000
2025-01-08	Verve Therapeutics, Inc.Stock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+488K sh	—	—	488,000
2025-01-08	Verve Therapeutics, Inc.Restricted Stock UnitsA Award	Director, Chief Executive Officer	AAward	+120K sh	—	—	120,000
2025-01-08	Verve Therapeutics, Inc.Stock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+150K sh	—	—	150,000
2024-12-04	Verve Therapeutics, Inc.G Gift	Director, Chief Executive Officer	GGift	−30K sh	—	—	323,508
2024-12-04	Verve Therapeutics, Inc.G Gift	Director, Chief Executive Officer	GGift	+30K sh	—	—	110,997
2024-06-28	Verve Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+30K sh	$2.87	+$86.1K	351,128
2024-06-28	Verve Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−30K sh	—	—	215,308
2024-06-03	RLAYRelay Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+102K sh	—	—	102,225
2024-02-14	Verve Therapeutics, Inc.Stock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+526K sh	—	—	526,000
2024-02-14	Verve Therapeutics, Inc.Restricted Stock UnitsA Award	Director, Chief Executive Officer	AAward	+132K sh	—	—	132,000
2023-05-31	RLAYRelay Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+66.1K sh	—	—	66,055
2023-02-14	Verve Therapeutics, Inc.Stock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+550K sh	—	—	550,200
2022-10-03	Verve Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+50K sh	$1.39	+$69.5K	367,839
2022-10-03	Verve Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−28.9K sh	$33.02	−$955K	338,928
2022-10-03	Verve Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−11.2K sh	$34.13	−$382K	327,743
2022-10-03	Verve Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−9,904 sh	$34.97	−$346K	317,839
2022-10-03	Verve Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−50K sh	—	—	138,995
2022-08-10	Verve Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+50K sh	$1.39	+$69.5K	367,839
2022-08-10	Verve Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−50K sh	$29.90	−$1.5M	317,839
2022-08-10	Verve Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−50K sh	—	—	167,425
2022-07-25	RLAYRelay Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+71.9K sh	—	—	71,881
2022-07-19	Verve Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+50K sh	$1.39	+$69.5K	367,839
2022-07-19	Verve Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−50K sh	$29.90	−$1.5M	317,839
2022-07-19	Verve Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−50K sh	—	—	217,425
2022-07-12	Verve Therapeutics, Inc.Stock Option (right to buy)G Gift	Director, Chief Executive Officer	GGift	−140K sh	—	—	291,988
2022-07-12	Verve Therapeutics, Inc.Stock Option (right to buy)G Gift	Director, Chief Executive Officer	GGift	−160K sh	—	—	445,308
2022-07-12	Verve Therapeutics, Inc.Stock Option (right to buy)G Gift	Director, Chief Executive Officer	GGift	+140K sh	—	—	140,000
2022-07-12	Verve Therapeutics, Inc.Stock Option (right to buy)G Gift	Director, Chief Executive Officer	GGift	+160K sh	—	—	300,000
2022-07-07	Verve Therapeutics, Inc.G Gift	Director, Chief Executive Officer	GGift	−160K sh	—	—	317,839
2022-07-07	Verve Therapeutics, Inc.G Gift	Director, Chief Executive Officer	GGift	+160K sh	—	—	240,997
2022-03-18	Verve Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+69.7K sh	$2.87	+$200K	477,525
2022-03-18	Verve Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−69.7K sh	—	—	605,308

Recent filings

Accepted (ET)
Sep 244
Kathiresan Sekar0001864112-25-000004
SEC(opens sec.gov)
Jul 284
Kathiresan Sekar0000950170-25-099260
SEC(opens sec.gov)
Jun 64
Kathiresan Sekar0000950170-25-083310
SEC(opens sec.gov)
Apr 34
Kathiresan Sekar0000950170-25-050563
SEC(opens sec.gov)
Jan 104
Kathiresan Sekar0000950170-25-003854
SEC(opens sec.gov)

Companies

Address

C/O VERVE THERAPEUTICS, INC. 201 BROOKLINE AVENUE, SUITE 601

BOSTON, MA, 02215